NVTIA® Ergothioneine for Healthy Aging and Skin Health
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-55
SponsorEUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
About this trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.
The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.
Eligibility criteria
Qualifiers
Male or female adults aged 35 to 55 years.
Generally healthy as determined by medical history, physical examination, and screening assessments.
Body Mass Index (BMI) between 18.5 and 29.9 kg/m².
Willing and able to provide written informed consent.
Disqualifiers
History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or psychiatric disease.
Current diagnosis of diabetes mellitus requiring medication.
Active inflammatory or autoimmune disease.
History of malignant disease within the previous five years.
Trial design
Treatments tested in this trial
- NVTIA® Ergothioneine
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov